Evidence Summary: Harms of Screening for Breast Cancer
Breast Cancer: Screening
January 11, 2016
Recommendations made by the USPSTF are independent of the U.S. government. They should not be construed as an official position of the Agency for Healthcare Research and Quality or the U.S. Department of Health and Human Services.
Harms of Breast Cancer Screening: Systematic Review to Update the 2009 U.S. Preventive Services Task Force Recommendation
By Heidi D. Nelson, MD, MPH; Miranda Pappas, MA; Amy Cantor, MD, MPH; Jessica Griffin, MS; Monica Daeges, BA; and Linda Humphrey, MD, MPH
The information in this article is intended to help clinicians, employers, policymakers, and others make informed decisions about the provision of health care services. This article is intended as a reference and not as a substitute for clinical judgment.
This article may be used, in whole or in part, as the basis for the development of clinical practice guidelines and other quality enhancement tools, or as a basis for reimbursement and coverage policies. AHRQ or U.S. Department of Health and Human Services endorsement of such derivative products may not be stated or implied.
This article was published online first at www.annals.org on January 12, 2016.
Background: In 2009, the U.S. Preventive Services Task Force recommended biennial mammography screening for women aged 50 to 74 years and selective screening for those aged 40 to 49 years.
Purpose: To review studies of screening in average-risk women with mammography, magnetic resonance imaging, or ultrasonography that reported on false-positive results, overdiagnosis, anxiety, pain, and radiation exposure.
Data Sources: MEDLINE and Cochrane databases through December 2014.
Study Selection: English-language systematic reviews, randomized trials, and observational studies of screening.
Data Extraction: Investigators extracted and confirmed data from studies and dual-rated study quality. Discrepancies were resolved through consensus.
Data Synthesis: Based on 2 studies of U.S. data, 10-year cumulative rates of false-positive mammography results and biopsies were higher with annual than biennial screening (61% vs. 42% and 7% vs. 5%, respectively) and for women aged 40 to 49 years, those with dense breasts, and those using combination hormone therapy. Twenty-nine studies using different methods reported overdiagnosis rates of 0% to 54%; rates from randomized trials were 11% to 22%. Women with false-positive results reported more anxiety, distress, and breast cancer–specific worry, although results varied across 80 observational studies. Thirtynine observational studies indicated that some women reported pain during mammography (1% to 77%); of these, 11% to 46% declined future screening. Models estimated 2 to 11 screening-related deaths from radiation-induced cancer per 100,000 women using digital mammography, depending on age and screening interval. Five observational studies of tomosynthesis and mammography indicated increased biopsies but reduced recalls compared with mammography alone.
Limitations: Studies of overdiagnosis were highly heterogeneous, and estimates varied depending on the analytic approach. Studies of anxiety and pain used different outcome measures. Radiation exposure was based on models.
Conclusion: False-positive results are common and are higher for annual screening, younger women, and women with dense breasts. Although overdiagnosis, anxiety, pain, and radiation exposure may cause harm, their effects on individual women are difficult to estimate and vary widely.
Primary Funding Source: Agency for Healthcare Research and Quality.
In 2009, the U.S. Preventive Services Task Force (USPSTF) recommended biennial mammography screening for women aged 50 to 74 years1 on the basis of evidence of benefits and harms.2, 3 The USPSTF concluded that screening decisions for women aged 40 to 49 years should be based on individual considerations and that evidence was insufficient to assess benefits and harms for those aged 75 years or older.1
Although there is general consensus that mammography screening is beneficial for many women, benefits must be weighed against potential harms to determine the net effect of screening on individual women. Determining the balance between benefits and harms is complicated by several important considerations that are unresolved, including defining and quantifying potential harms; the optimal ages at which to begin and end routine screening; the optimal screening intervals; appropriate use of various imaging modalities, including supplemental technologies; values and preferences of women in regards to screening; and how all of these considerations vary depending on a woman's risk for breast cancer.
This systematic review updates evidence for the USPSTF on the harms of breast cancer screening, including false-positive mammography results, overdiagnosis, anxiety, pain during procedures, and radiation exposure, and how these adverse effects vary by age, risk factor, screening interval, and screening modality. Systematic reviews of the effectiveness of screening,4 performance characteristics of screening methods,5 and the accuracy of breast density determination and use of supplemental screening technologies6 are provided in additional reports.
Scope, Key Questions, and Analytic Framework
The USPSTF determined the scope and key questions for this review by using established methods.7, 8 A standard protocol was developed and publicly posted on the USPSTF Web site. A technical report further describes the methods and includes search strategies and additional information.4
Investigators created an analytic framework outlining the key questions, patient populations, interventions, and outcomes reviewed (Appendix Figure 1). Key questions include the harms of routine breast cancer screening and how they differ by age, risk factor, screening interval, and screening modality (mammography [film, digital, or tomosynthesis], magnetic resonance imaging [MRI], and ultrasonography). Harms include false-positive and false-negative mammography results, overdiagnosis, anxiety and other psychological responses, pain during procedures, and radiation exposure. Overdiagnosis refers to women receiving a diagnosis of ductal carcinoma in situ (DCIS) or invasive breast cancer when they have abnormal lesions that are unlikely to become clinically evident during their lifetime in the absence of screening. Overdiagnosed women may be harmed by unnecessary procedures and treatments as well as by the burden of receiving a cancer diagnosis.
The target population for the USPSTF recommendation includes women aged 40 years or older and excludes women with known physical signs or symptoms of breast abnormalities and those at high risk for breast cancer whose surveillance and management are beyond the scope of the USPSTF recommendations for preventive services (preexisting breast cancer or high-risk breast lesions, hereditary genetic syndromes associated with breast cancer, and previous large doses of chest radiation before age 30 years). Risk factors considered in this review are common among women who are not at high risk for breast cancer9 (described in Appendix Figure 1).
Data Sources and Searches
A research librarian conducted electronic searches of the Cochrane Central Register of Controlled Trials, the Cochrane Database of Systematic Reviews, and Ovid MEDLINE through December 2014 for relevant studies and systematic reviews. Searches were supplemented by references identified from additional sources, including reference lists and experts. Studies of harms included in the previous systematic review for the USPSTF2, 3 were also included.
Two investigators independently evaluated each study to determine eligibility based on prespecified inclusion criteria. Discrepancies were resolved through consensus.
We included recently published systematic reviews; randomized, controlled trials (RCTs); and observational studies of prespecified harms. When available, studies providing outcomes specific to age, risk factors, screening intervals, and screening modalities were preferred over studies providing general outcomes. Studies that were most clinically relevant to practice in the United States were selected; relevance was determined by practice setting, population, date of publication, and use of technologies and therapies in current practice. Studies meeting criteria for high quality and with designs ranked higher in the study design–based hierarchy of evidence were emphasized because they are less susceptible to bias (for example, RCTs were chosen over observational studies).
Data Extraction and Quality Assessment
Details of the study design, patient population, setting, screening method, interventions, analysis, followup, and results were abstracted by one investigator and confirmed by another. Two investigators independently applied criteria developed by the USPSTF7, 8 to rate the quality of each RCT, cohort study, case–control study, and systematic review as good, fair, or poor; criteria to rate studies with other designs included in this review are not available. Discrepancies were resolved through consensus.
Studies meeting inclusion criteria were qualitatively synthesized. Most studies in this review had designs for which quality rating criteria are not available, which limited data synthesis. When possible, we assessed the aggregate internal validity (quality) of the body of evidence for each key question (good, fair, or poor) by using methods developed by the USPSTF based on the number, quality, and size of studies; consistency of results between studies; and directness of evidence.7, 8
Role of the Funding Source
This research was funded by the Agency for Healthcare Research and Quality (AHRQ) under a contract to support the work of the USPSTF. The investigators worked with USPSTF members and AHRQ staff to develop and refine the scope, analytic frameworks, and key questions; resolve issues during the project; and finalize the report. AHRQ had no role in study selection, quality assessment, synthesis, or development of conclusions. AHRQ provided project oversight; reviewed the draft report; and distributed the draft for peer review, including to representatives of professional societies and federal agencies. AHRQ performed a final review of the manuscript to ensure that the analysis met methodological standards. The investigators are solely responsible for the content and the decision to submit the manuscript for publication.
Of the 12,004 abstracts identified by searches and other sources, 59 studies met inclusion criteria for key questions in this report, including 10 systematic reviews of 134 studies and 49 additional studies (Appendix Figure 2).
False-Positive Mammography Results
Two new observational studies estimated the cumulative probability of false-positive results after 10 years of screening with film and digital mammography, based on data from the Breast Cancer Surveillance Consortium, a large population-based database in the United States (Appendix Table 1).10, 11 When screening began at age 40 years, the cumulative probability of receiving at least 1 false-positive mammography result after 10 years was 61% (95% CI, 59% to 63%) with annual screening and 42% (CI, 41% to 43%) with biennial screening.10 Estimates were similar when screening began at age 50 years. The cumulative probability of receiving a biopsy recommendation due to a false-positive mammography result after 10 years of screening was 7% (CI, 6% to 8%) with annual screening versus 5% (CI, 4% to 5%) with biennial screening for women who initiated screening at age 40 years and 9% (CI, 7% to 12%) with annual screening versus 6% (CI, 6% to 7%) with biennial screening for those who began at age 50 years.
In a separate analysis, rates of false-positive mammography results were highest among women receiving annual mammography who had extremely dense breasts and either were aged 40 to 49 years (65.5%) or used combination hormone therapy (65.8%).11 The highest rates of biopsy due to false-positive mammography results were related to similar characteristics and ranged from 12% to 14%. Rates of false-positive mammography results were lower among women aged 50 to 74 years who were receiving biennial or triennial mammography and had breasts with scattered fibroglandular densities (39.7% and 21.9%, respectively) or almost entirely fat breast density (17.4% and 12.1%, respectively), regardless of estrogen use.
A meta-analysis of 3 RCTs,13, 14 a systematic review of 13 observational studies,15 and 18 new individual studies16–33 of overdiagnosis were identified for this update4 (Appendix Table 2). Estimates were primarily based on screening trials, screening programs and registries, or modeled data. Studies differed by patient populations; screening and follow-up times; screening policies, uptake, and intensity; and underlying cancer incidence trends. In addition, at least 7 different measures of overdiagnosis were reported.19 Estimates differed in their numerators and denominators, whether they included both invasive cancer and DCIS, their assumptions about lead time and progression of invasive cancer and DCIS, and whether they reported relative or absolute changes.
Various methods were used to estimate overdiagnosis. The most common methods determined the difference in cancer incidence in the presence and absence of screening (observed excess incidence approach) or made inferences about the lead time or natural history of breast cancer and estimated the corresponding frequency of overdiagnosis (lead-time approach).35 How differences in study characteristics, measures, and methods affect estimates of overdiagnosis has been well-described,13, 14, 19, 35–37 yet there is no consensus about the appropriate approach14 and there are no quality rating criteria to evaluate studies.
Estimates From RCTs
Data from 3 RCTs that did not screen control participants at the end of the trials were considered to be the least biased estimates of overdiagnosis in a comprehensive review.13, 14 The Malmö I trial and the Canadian National Breast Screening Study (CNBSS-1 and CNBSS-2) provided estimates from randomized comparison groups with follow-up that extended sufficiently beyond the screening period to differentiate earlier diagnosis from overdiagnosis.13 However, their approaches differed: the Malmö I trial included all breast cancer cases, and the Canadian trials included only those detected by screening.
Results of the Malmö I trial34 and the 2 Canadian trials38, 39 were used to compare the excess incidence of breast cancer (both invasive cancer and DCIS) in the screening population with the incidence in the absence of screening. Overdiagnosis was estimated at 10.7% (CI, 9.3% to 12.2%)13, 14 when only cases identified during the screening period were included and 19.0% (CI, 15.2% to 22.7%) when cases identified throughout screening and follow-up were included. Estimates for women aged 40 to 49 years in CNBSS-1 (12.4% for shorter accrual and 22.7% for longer accrual) were higher than for those aged 50 to 59 years in CNBSS-2 (9.7% and 16.0%, respectively) and those aged 55 to 69 years in the Malmö I trial (10.5% and 18.7%, respectively). Recently published long-term follow-up of the 2 Canadian trials (15 years after enrollment) indicated a 22% overdiagnosis rate for invasive cancer for the combined age groups.31
Estimates From Observational Studies
Unadjusted estimates from 13 observational studies included in a systematic review indicated overdiagnosis rates ranging from 0% to 54%, and 6 studies that adjusted for breast cancer risk and lead time indicated rates ranging from 1% to 10%.15 Estimates from other studies fall within this overall broad range.
Anxiety, Distress, and Other Psychological Responses
Four systematic reviews of 70 unique studies40–43 (Table 1) and 10 additional observational studies44–53 (Table 2) published after the systematic reviews described adverse psychological effects of screening. Although several studies met criteria for fair or good quality, most were limited by enrollment of small numbers of narrowly selected participants, use of various self-reported measures, differential attrition or response rates, and low clinical applicability. No studies provided results by age, risk factor, screening interval, or screening modality.
Results of systematic reviews indicated that women who received clear communication of their negative mammography results had minimal anxiety, whereas those recalled for further testing had more anxiety, breast cancer–specific worry, and distress.40, 42, 54– 57 Some women had persistent anxiety despite eventual negative results,56, 58–61 whereas some showed only transient anxiety.54, 62–68 Among studies that evaluated reattendance rates, 2 studies reported that women with false-positive results were less likely to return for their next screening mammography56, 69 and 2 studies reported no differences.70, 71 One study reported an increase in reattendance when women were given letters tailored to their last screening result (risk ratio, 1.10 [CI, 1.00 to 1.21]).72
Five new observational studies compared psychological outcomes in women receiving false-positive results versus those receiving normal results44, 46–48, 50 and reported findings similar to those of the reviews. Women with false-positive results had more breast cancer–specific worry (49% vs. 10%; P < 0.0001), more worries that affected mood or daily activities (31% vs. 2%; P < 0.0001),48 and lower mental functioning (mean mental functioning score on the Short Form-36 at 6 months, 80.6 vs. 85.0; P = 0.03) and vitality (mean vitality score on the Short Form-36 at 6 months, 70.3 vs. 77.0; P = 0.02).50 They also had increased measures of depression (mean score on the depression subscale of the Hospital Anxiety and Depression Scale at 6 months, 3.2 vs. 2.4; P = 0.045); however, scores were below clinical thresholds for depression.50 An analysis of racial subgroups in a large study indicated increased depression scores among nonwhite women with false-positive results (odds ratio, 3.23 [CI, 1.32 to 7.91]).44 Three studies found lower reattendance rates for women with false-positive results51, 52 or biopsies,51, 53 but reattendance sometimes varied by specific circumstances, such as age or type of biopsy.51
Pain During Procedures
Two systematic reviews included 39 unique studies of pain associated with screening procedures,73, 74 and a separate systematic review included 7 trials of interventions to reduce pain75 (Appendix Table 3). Results indicated that many women had pain (range, 1% to 77%) but few considered it a deterrent to future screening.73 In these studies, pain was associated with stage of the menstrual cycle, anxiety, and the anticipation of pain.
In a review of studies of pain or discomfort after screening mammography and their effect on screening reattendance,74 actual nonreattendance due to concerns about pain ranged from 11% to 46% (5 studies) and intended future nonreattendance ranged from 3% to 18% (2 studies). Fifteen studies that did not directly ask about reasons for nonreattendance found no differences in actual reattendance between women who had pain and those who did not (risk ratio, 1.38 [CI, 0.94 to 2.02]) (5 studies).74 However, nonreattenders had significantly higher pain scores than reattenders in 2 of 3 studies.76–78 Two studies reported lower intent to reattend among women with pain, whereas 3 others reported no differences in intended reattendance and pain.79–83
A systematic review of trials of interventions to reduce pain associated with mammography screening75 found that providing verbal or written information to women reduced discomfort in 2 studies84, 85 but not in a third.86 Studies of different breast compression strategies87, 88 or premedication with acetaminophen89 indicated no differences in discomfort, whereas use of a breast cushion reduced pain.90
No studies directly measured the association between radiation exposure from mammography screening and the incidence of breast cancer and death. Two-view digital mammography and screen-film mammography involve average mean glandular radiation doses of 3.7 and 4.7 mGy, respectively, and are considered to provide low-dose, low-energy radiation exposure.
Two modeling studies provided estimates of radiation exposure, breast cancer incidence, and death91, 92 (Appendix Table 4). A model predicting the number of breast cancer cases attributable to the radiation dose of a single typical digital mammogram estimated that the number of deaths due to radiation-induced cancer ranged from 2 per 100,000 in women aged 50 to 59 years screened biennially to 11 per 100,000 in those aged 40 to 59 years screened annually.92
Differences Between Screening Modalities
Six observational studies compared false-positive recall rates with screening using mammography and tomosynthesis93–97 or clinical breast examination98 versus mammography alone (Appendix Table 5). No studies evaluated MRI screening in women who were not at high risk for breast cancer.
Four of 5 studies showed statistically significantly lower rates of recall for tomosynthesis and mammography than for mammography alone.93–97 Although recalls were reduced by 16 per 1000 women (CI, 18 to 14 recalls; P < 0.001) in one U.S. study, biopsies increased by 1.3 per 1000 women (CI, 0.4 to 2.1 biopsies; P = 0.004).93 A smaller U.S. study showed reduced recall rates with tomosynthesis and mammography versus mammography alone after controlling for age, breast density, and breast cancer risk (adjusted odds ratio, 0.62 [CI, 0.55 to 0.70]; P < 0.0001),97 whereas another study indicated no reductions.94 Two European studies also reported lower rates of recall for women screened with tomosynthesis and mammography (1% vs. 2% [P < 0.0001]95 and 53 vs. 61 per 1000 women [P = 0.001]96).
Women receiving mammography and clinical breast examination had more recalls than those receiving mammography alone in a study from Canada (8.7% vs. 6.5%; 55 additional recalls per 10,000 women).98
A summary of the evidence is provided in Table 3. Two large observational studies of women screened in the Breast Cancer Surveillance Consortium provided good-quality evidence about cumulative rates of false-positive mammography results and biopsies over 10 years. In these studies, rates were higher with annual than biennial screening (mammography, 61% vs. 42%; biopsy, 7% vs. 5%) and for women with heterogeneously or extremely dense breasts, those aged 40 to 49 years, and those using combination hormone therapy. These results are consistent with those of an earlier study indicating cumulative 10-year rates of false-positive mammography results of 49% overall and 56% for women aged 40 to 49 years, with an overall biopsy rate of 19%.12 The results of these highly clinically applicable studies can be used to inform women of the likelihood of false-positive results and additional procedures with mammography screening in the United States, particularly for women with characteristics associated with the highest rates of false-positive results.
Despite much research, the evidence for determining overdiagnosis is poor. There is no consensus definition of overdiagnosis, and there are no criteria on which to base critical appraisal of studies. Studies are highly heterogeneous, and estimates vary depending on the analytic approach. Possibly the least biased estimates were derived from 3 RCTs that indicated rates of 11% to 22%. Unadjusted estimates from 13 observational studies ranged from 0% to 54%, and 6 studies that adjusted for breast cancer risk and lead time found rates ranging from 1% to 10%. Until methodological standards for estimating overdiagnosis are more clearly defined, the correct estimate is uncertain.
Although overdiagnosis is an important outcome of screening, it is difficult to evaluate in individual women because it is based on knowing whether a specific lesion will progress and what its effect will be on a woman's health. Women who are overdiagnosed can be harmed by unnecessary procedures and treatments and by the burden of receiving a cancer diagnosis. The introduction of technology capable of detecting even smaller suspicious lesions may also lead to increased overdiagnosis. Understanding the concept of overdiagnosis is important to appropriately inform women about the benefits and harms of screening despite current limitations in determining its effect on individual women.
The effect of screening on anxiety and pain is supported by fair-level evidence that includes a large number of predominantly descriptive observational studies. In general, women with false-positive results have more anxiety and distress than those with normal results. Anxiety lessens over time for most women but persists for others, and some women with false-positive results do not attend subsequent screenings. Although many women have pain during mammography, the proportion of those who do not attend subsequent screenings varies. Studies indicate that the experiences of falsepositive results and pain during mammography differ widely among women but are important for many of them. Additional efforts to reduce false-positive results and improve how they are communicated and to recognize and reduce pain during procedures could improve the balance of benefits and harms of screening for many women.
The harms of radiation exposure from mammography screening are based on only 2 modeling studies. The number of deaths due to radiation-induced cancer from screening with digital mammography was estimated to be 2 to 11 per 100,000 women, depending on age and screening intervals. As imaging technologies change, this estimate could improve or worsen depending on the uptake of supplemental imaging with tomosynthesis as well as additional imaging for falsepositive results. Reducing radiation exposure through more effective imaging is an important area of future research.
Five observational studies described false-positive results with the use of tomosynthesis. This evidence is limited by the lack of randomized trials, uncertainty about the comparability of comparison groups, and differences in outcome measures. A U.S. study comparing tomosynthesis and mammography versus mammography alone reported a significant reduction of 16 recalls but an increase of 1.3 biopsies per 1000 women. Available studies of screening with MRI or ultrasonography focus on high-risk women and are outside the scope of this systematic review. No randomized trials of the efficacy of the different imaging technologies for breast cancer screening have been published, and evidence on their benefits and harms for screening recommendations is lacking.
Limitations of this review include the use of English-language articles only, which could have resulted in language bias, although we did not identify non–English-language studies that otherwise met inclusion criteria in our searches. We included only studies that are applicable to current practice in the United States to improve clinical relevance for the USPSTF. The number, quality, and applicability of studies varied widely, and most studies were observational, with designs for which quality rating criteria are not available. In conclusion, false-positive results are common and lead to additional imaging and biopsies, particularly with annual screening and among younger women and those with dense breasts. Although overdiagnosis, anxiety, pain, and radiation exposure may cause harm, their effects on individual women are difficult to estimate and vary widely.
Source: This article was published at www.annals.org on January 12, 2016.
Disclaimer: The findings and conclusions in this article are those of the authors, who are responsible for its content, and do not necessarily represent the views of the AHRQ. No statement in this report should be construed as an official position of the AHRQ or the U.S. Department of Health and Human Services.
Acknowledgment: The authors thank Andrew Hamilton, MLS, MS, for conducting literature searches and Spencer Dandy, BS, for assisting with manuscript preparation at the Pacific Northwest Evidence-based Practice Center at Oregon Health & Science University; Alison Conlin, MD, MPH, and Michael Neuman, MD, at the Providence Cancer Center at Providence Health & Services Oregon, and Arpana Naik, MD, at Oregon Health & Science University for providing medical expertise; Jennifer Croswell, MD, MPH, at AHRQ; and USPSTF members Linda Baumann, PhD, RN, Kirsten Bibbins-Domingo, PhD, MD, MAS, Mark Ebell, MD, MS, Jessica Herzstein, MD, MPH, Michael LeFevre, MD, MSPH, and Douglas Owens, MD, MS.
Financial Support: By AHRQ (Contract No. 290-2012-00015-I, Task Order 2), Rockville, Maryland.
Disclosures: Drs. Nelson, Cantor, and Humphrey; Ms. Pappas; Ms. Griffin; and Ms. Daeges report grants from AHRQ during the conduct of this study. Forms can be viewed at www.acponline.org/authors/icmje/ConflictOfInterestForms.do?msNum=M15-0970.
Requests for Single Reprints: Heidi D. Nelson, MD, MPH, Oregon Health & Science University, 3181 SW Sam Jackson Park Road, Mail Code BICC, Portland, OR 97239; e-mail, firstname.lastname@example.org.
1. U.S. Preventive Services Task Force. Screening for breast cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med. 2009;151:716-26. [PMID: 19920272]
2. Nelson HD, Tyne K, Naik A, Bougatsos C, Chan B, Nygren P, et al. Screening for Breast Cancer: Systematic Evidence Review Update for the US Preventive Services Task Force. AHRQ Publication No. 10- 05142-EF-1. Rockville, MD: Agency for Healthcare Research and Quality; 2009. [PMID: 20722173] Accessed at www.ncbi.nlm.nih.gov/pubmed/20722173 on 19 September 2014.
3. Nelson HD, Tyne K, Naik A, Bougatsos C, Chan BK, Humphrey L; U.S. Preventive Services Task Force. Screening for breast cancer: an update for the U.S. Preventive Services Task Force. Ann Intern Med. 2009;151:727-37. [PMID: 19920273]
4. Nelson HD, Cantor A, Humphrey L, Fu R, Pappas M, Daeges M, et al. Screening for Breast Cancer: A Systematic Review to Update the 2009 U.S. Preventive Services Task Force Recommendation. Evidence Synthesis No. 124. AHRQ Publication No. 14-05201-EF-1. Rockville, MD: Agency for Healthcare Research and Quality; 2016.
5. Melnikow J, Fenton JJ, Whitlock E, Miglioretti D, Weyrich M, Thompson J, et al. Supplemental Screening for Breast Cancer in Women With Dense Breasts: A Systematic Review for the U.S. Preventive Services Task Force. Evidence Synthesis No. 126. AHRQ Publication No. 14-05201-EF-2. Rockville, MD: Agency for Healthcare Research and Quality; 2016.
6. Melnikow J, Fenton JJ, Miglioretti D, Whitlock E, Weyrich M. Screening for Breast Cancer With Digital Breast Tomosynthesis. Evidence Synthesis No. 125. AHRQ Publication No. 14-05201-EF-2. Rockville, MD: Agency for Healthcare Research and Quality; 2016.
7. Harris RP, Helfand M, Woolf SH, Lohr KN, Mulrow CD, Teutsch SM, et al; Methods Work Group, Third US Preventive Services Task Force. Current methods of the US Preventive Services Task Force: a review of the process. Am J Prev Med. 2001;20:21-35. [PMID: 11306229]
8. U.S. Preventive Services Task Force. Procedure Manual. Rockville, MD: U.S. Preventive Services Task Force; 2015.
9. Nelson HD, Zakher B, Cantor A, Fu R, Griffin J, O'Meara ES, et al. Risk factors for breast cancer for women aged 40 to 49 years: a systematic review and meta-analysis. Ann Intern Med. 2012;156:635-48. [PMID: 22547473]
10. Hubbard RA, Kerlikowske K, Flowers CI, Yankaskas BC, Zhu W, Miglioretti DL. Cumulative probability of false-positive recall or biopsy recommendation after 10 years of screening mammography: a cohort study. Ann Intern Med. 2011;155:481-92. [PMID: 22007042]
11. Kerlikowske K, Zhu W, Hubbard RA, Geller B, Dittus K, Braithwaite D, et al; Breast Cancer Surveillance Consortium. Outcomes of screening mammography by frequency, breast density, and postmenopausal hormone therapy. JAMA Intern Med. 2013;173:807-16. [PMID: 23552817]
12. Elmore JG, Barton MB, Moceri VM, Polk S, Arena PJ, Fletcher SW. Ten-year risk of false positive screening mammograms and clinical breast examinations. N Engl J Med. 1998;338:1089-96. [PMID: 9545356]
13. Marmot MG, Altman DG, Cameron DA, Dewar JA, Thompson SG, Wilcox M. The benefits and harms of breast cancer screening: an independent review. Br J Cancer. 2013;108:2205-40. [PMID: 23744281]
14. Independent UK Panel on Breast Cancer Screening. The benefits and harms of breast cancer screening: an independent review. Lancet. 2012;380:1778-86. [PMID: 23117178]
15. Puliti D, Duffy SW, Miccinesi G, de Koning H, Lynge E, Zappa M, et al; EUROSCREEN Working Group. Overdiagnosis in mammographic screening for breast cancer in Europe: a literature review. J Med Screen. 2012;19(Suppl 1):42-56. [PMID: 22972810]
16. Bleyer A, Welch HG. Effect of three decades of screening mammography on breast-cancer incidence. N Engl J Med. 2012;367:1998-2005. [PMID: 23171096]
17. Coldman A, Phillips N. Incidence of breast cancer and estimates of overdiagnosis after the initiation of a population-based mammography screening program. CMAJ. 2013;185:E492-8. [PMID: 23754101]
18. de Gelder R, Fracheboud J, Heijnsdijk EA, den Heeten G, Verbeek AL, Broeders MJ, et al. Digital mammography screening: weighing reduced mortality against increased overdiagnosis. Prev Med. 2011;53:134-40. [PMID: 21718717]
19. de Gelder R, Heijnsdijk EA, van Ravesteyn NT, Fracheboud J, Draisma G, de Koning HJ. Interpreting overdiagnosis estimates in population-based mammography screening. Epidemiol Rev. 2011;33:111-21. [PMID: 21709144]
20. Falk RS, Hofvind S, Skaane P, Haldorsen T. Overdiagnosis among women attending a population-based mammography screening program. Int J Cancer. 2013;133:705-12. [PMID: 23355313]
21. Hellquist BN, Duffy SW, Nyström L, Jonsson H. Overdiagnosis in the population-based service screening programme with mammography for women aged 40 to 49 years in Sweden. J Med Screen. 2012;19:14-9. [PMID: 22355181]
22. Jørgensen KJ, Zahl PH, Gøtzsche PC. Overdiagnosis in organised mammography screening in Denmark. A comparative study. BMC Womens Health. 2009;9:36. [PMID: 20028513]
23. Kalager M, Adami HO, Bretthauer M, Tamimi RM. Overdiagnosis of invasive breast cancer due to mammography screening: results from the Norwegian screening program. Ann Intern Med. 2012;156:491-9. [PMID: 22473436]
24. Martinez-Alonso M, Vilaprinyo E, Marcos-Gragera R, Rue M. Breast cancer incidence and overdiagnosis in Catalonia (Spain). Breast Cancer Res. 2010;12:R58. [PMID: 20682042]
25. Morrell S, Barratt A, Irwig L, Howard K, Biesheuvel C, Armstrong B. Estimates of overdiagnosis of invasive breast cancer associated with screening mammography. Cancer Causes Control. 2010;21:275-82. [PMID: 19894130]
26. Njor SH, Olsen AH, Blichert-Toft M, Schwartz W, Vejborg I, Lynge E. Overdiagnosis in screening mammography in Denmark: population based cohort study. BMJ. 2013;346:f1064. [PMID: 23444414]
27. Puliti D, Zappa M, Miccinesi G, Falini P, Crocetti E, Paci E. An estimate of overdiagnosis 15 years after the start of mammographic screening in Florence. Eur J Cancer. 2009;45:3166-71. [PMID: 19879130]
28. Seigneurin A, François O, Labarère J, Oudeville P, Monlong J, Colonna M. Overdiagnosis from non-progressive cancer detected by screening mammography: stochastic simulation study with calibration to population based registry data. BMJ. 2011;343:d7017. [PMID: 22113564]
29. Yen AM, Duffy SW, Chen TH, Chen LS, Chiu SY, Fann JC, et al. Long-term incidence of breast cancer by trial arm in one county of the Swedish Two-County Trial of mammographic screening. Cancer. 2012;118:5728-32. [PMID: 22605639]
30. Zahl PH, Mæhlen J. Overdiagnosis of breast cancer after 14 years of mammography screening. Tidsskr Nor Laegeforen. 2012;132:414-7. [PMID: 22353833]
31. Miller AB, Wall C, Baines CJ, Sun P, To T, Narod SA. Twenty five year follow-up for breast cancer incidence and mortality of the Canadian National Breast Screening Study: randomised screening trial. BMJ. 2014;348:g366. [PMID: 24519768]
32. Gunsoy NB, Garcia-Closas M, Moss SM. Estimating breast cancer mortality reduction and overdiagnosis due to screening for different strategies in the United Kingdom. Br J Cancer. 2014;110:2412-9. [PMID: 24762956]
33. Duffy SW, Tabar L, Olsen AH, Vitak B, Allgood PC, Chen TH, et al. Absolute numbers of lives saved and overdiagnosis in breast cancer screening, from a randomized trial and from the Breast Screening Programme in England. J Med Screen. 2010;17:25-30. [PMID: 20356942]
34. Zackrisson S, Andersson I, Janzon L, Manjer J, Garne JP. Rate of over-diagnosis of breast cancer 15 years after end of Malmö mammographic screening trial: follow-up study. BMJ. 2006;332:689-92. [PMID: 16517548]
35. Etzioni R, Gulati R, Mallinger L, Mandelblatt J. Influence of study features and methods on overdiagnosis estimates in breast and prostate cancer screening. Ann Intern Med. 2013;158:831-8. [PMID: 23732716]
36. Duffy SW, Lynge E, Jonsson H, Ayyaz S, Olsen AH. Complexities in the estimation of overdiagnosis in breast cancer screening. Br J Cancer. 2008;99:1176-8. [PMID: 18766185]
37. Biesheuvel C, Barratt A, Howard K, Houssami N, Irwig L. Effects of study methods and biases on estimates of invasive breast cancer overdetection with mammography screening: a systematic review. Lancet Oncol. 2007;8:1129-38. [PMID: 18054882]
38. Miller AB, To T, Baines CJ, Wall C. Canadian National Breast Screening Study-2: 13-year results of a randomized trial in women aged 50-59 years. J Natl Cancer Inst. 2000;92:1490-9. [PMID: 10995804]
39. Miller AB, To T, Baines CJ, Wall C. The Canadian National Breast Screening Study-1: breast cancer mortality after 11 to 16 years of follow-up. A randomized screening trial of mammography in women age 40 to 49 years. Ann Intern Med. 2002;137:305-12. [PMID: 12204013]
40. Brett J, Bankhead C, Henderson B, Watson E, Austoker J. The psychological impact of mammographic screening. A systematic review. Psychooncology. 2005;14:917-38. [PMID: 15786514]
41. Brewer NT, Salz T, Lillie SE. Systematic review: the long-term effects of false-positive mammograms. Ann Intern Med. 2007;146:502-10. [PMID: 17404352]
42. Hafslund B, Nortvedt MW. Mammography screening from the perspective of quality of life: a review of the literature. Scand J Caring Sci. 2009;23:539-48. [PMID: 19170959]
43. Bond M, Pavey T, Welch K, Cooper C, Garside R, Dean S, et al. Psychological consequences of false-positive screening mammograms in the UK. Evid Based Med. 2013;18:54-61. [PMID: 22859786]
44. Gibson CJ, Weiss J, Goodrich M, Onega T. False-positive mammography and depressed mood in a screening population: findings from the New Hampshire Mammography Network. J Public Health (Oxf). 2009;31:554-60. [PMID: 19574274]
45. Keyzer-Dekker CM, De Vries J, van Esch L, Ernst MF, Nieuwenhuijzen GA, Roukema JA, et al. Anxiety after an abnormal screening mammogram is a serious problem. Breast. 2012;21:83-8. [PMID: 21924905]
46. Brodersen J, Siersma VD. Long-term psychosocial consequences of false-positive screening mammography. Ann Fam Med. 2013;11:106-15. [PMID: 23508596]
47. Tosteson AN, Fryback DG, Hammond CS, Hanna LG, Grove MR, Brown M, et al. Consequences of false-positive screening mammograms. JAMA Intern Med. 2014;174:954-61. [PMID: 24756610]
48. Espasa R, Murta-Nascimento C, Bayés R, Sala M, Casamitjana M, Macià F, et al. The psychological impact of a false-positive screening mammogram in Barcelona. J Cancer Educ. 2012;27:780-5. [PMID: 22477233]
49. Schou Bredal I, Kåresen R, Skaane P, Engelstad KS, Ekeberg Ø. Recall mammography and psychological distress. Eur J Cancer. 2013;49:805-11. [PMID: 23021930]
50. Hafslund B, Espehaug B, Nortvedt MW. Effects of false-positive results in a breast screening program on anxiety, depression and health-related quality of life. Cancer Nurs. 2012;35:E26-34. [PMID: 22067696]
51. Fitzpatrick P, Fleming P, O'Neill S, Kiernan D, Mooney T. Falsepositive mammographic screening: factors influencing reattendance over a decade of screening. J Med Screen. 2011;18:30-3. [PMID: 21536814]
52. Klompenhouwer EG, Duijm LE, Voogd AC, den Heeten GJ, Strobbe LJ, Louwman MW, et al. Re-attendance at biennial screening mammography following a repeated false positive recall. Breast Cancer Res Treat. 2014;145:429-37. [PMID: 24748569]
53. Maxwell AJ, Beattie C, Lavelle J, Lyburn I, Sinnatamby R, Garnett S, et al. The effect of false positive breast screening examinations on subsequent attendance: retrospective cohort study. J Med Screen. 2013;20:91-8. [PMID: 24009091]
54. Lowe JB, Balanda KP, Del Mar C, Hawes E. Psychologic distress in women with abnormal findings in mass mammography screening. Cancer. 1999;85:1114-8. [PMID: 10091796]
55. Hislop TG, Harris SR, Jackson J, Thorne SE, Rousseau EJ, Coldman AJ, et al. Satisfaction and anxiety for women during investigation of an abnormal screening mammogram. Breast Cancer Res Treat. 2002;76:245-54. [PMID: 12462385]
56. Brett J, Austoker J. Women who are recalled for further investigation for breast screening: psychological consequences 3 years after recall and factors affecting re-attendance. J Public Health Med. 2001;23:292-300. [PMID: 11873891]
57. Ong G, Austoker J, Brett J. Breast screening: adverse psychological consequences one month after placing women on early recall because of a diagnostic uncertainty. A multicentre study. J Med Screen. 1997;4:158-68. [PMID: 9368874]
58. Aro AR, Pilvikki Absetz S, van Elderen TM, van der Ploeg E, van der Kamp LJ. False-positive findings in mammography screening induces short-term distress-breast cancer-specific concern prevails longer. Eur J Cancer. 2000;36:1089-97. [PMID: 10854941]
59. Brett J, Austoker J, Ong G. Do women who undergo further investigation for breast screening suffer adverse psychological consequences? A multi-centre follow-up study comparing different breast screening result groups five months after their last breast screening appointment. J Public Health Med. 1998;20:396-403. [PMID: 9923945]
60. Lerman C, Trock B, Rimer BK, Boyce A, Jepson C, Engstrom PF. Psychological and behavioral implications of abnormal mammograms. Ann Intern Med. 1991;114:657-61. [PMID: 2003712]
61. Lampic C, Thurfjell E, Sjödén PO. The influence of a false-positive mammogram on a woman's subsequent behaviour for detecting breast cancer. Eur J Cancer. 2003;39:1730-7. [PMID: 12888368]
62. Cockburn J, Staples M, Hurley SF, De Luise T. Psychological consequences of screening mammography. J Med Screen. 1994;1:7-12. [PMID: 8790480]
63. Ekeberg Ø, Skjauff H, Kåresen R. Screening for breast cancer is associated with a low degree of psychological distress. Breast. 2001;10:20-4. [PMID: 14965553]
64. Gilbert FJ, Cordiner CM, Affleck IR, Hood DB, Mathieson D, Walker LG. Breast screening: the psychological sequelae of falsepositive recall in women with and without a family history of breast cancer. Eur J Cancer. 1998;34:2010-4. [PMID: 10070302]
65. Gram IT, Lund E, Slenker SE. Quality of life following a false positive mammogram. Br J Cancer. 1990;62:1018-22. [PMID: 2257206]
66. Lampic C, Thurfjell E, Bergh J, Sjödén PO. Short- and long-term anxiety and depression in women recalled after breast cancer screening. Eur J Cancer. 2001;37:463-9. [PMID: 11267855]
67. Lidbrink E, Levi L, Pettersson I, Rosendahl I, Rutqvist LE, de la Torre B, et al. Single-view screening mammography: psychological, endocrine and immunological effects of recalling for a complete three-view examination. Eur J Cancer. 1995;31A:932-3. [PMID: 7646925]
68. Sandin B, Chorot P, Valiente RM, Lostao L, Santed MA. Adverse psychological effects in women attending a second-stage breast cancer screening. J Psychosom Res. 2002;52:303-9. [PMID: 12023127]
69. McCann J, Stockton D, Godward S. Impact of false-positive mammography on subsequent screening attendance and risk of cancer. Breast Cancer Res. 2002;4:R11. [PMID: 12223128]
70. O'Sullivan I, Sutton S, Dixon S, Perry N. False positive results do not have a negative effect on reattendance for subsequent breast screening. J Med Screen. 2001;8:145-8. [PMID: 11678554]
71. Orton M, Fitzpatrick R, Fuller A, Mant D, Mlynek C, Thorogood M. Factors affecting women's response to an invitation to attend for a second breast cancer screening examination. Br J Gen Pract. 1991;41:320-2. [PMID: 1777275]
72. Meldrum P, Turnbull D, Dobson HM, Colquhoun C, Gilmour WH, McIlwaine GM. Tailored written invitations for second round breast cancer screening: a randomised controlled trial. J Med Screen. 1994;1:245-8. [PMID: 8790529]
73. Armstrong K, Moye E, Williams S, Berlin JA, Reynolds EE. Screening mammography in women 40 to 49 years of age: a systematic review for the American College of Physicians. Ann Intern Med. 2007;146:516-26. [PMID: 17404354]
74. Whelehan P, Evans A, Wells M, Macgillivray S. The effect of mammography pain on repeat participation in breast cancer screening: a systematic review. Breast. 2013;22:389-94. [PMID: 23541681]
75. Miller D, Livingstone V, Herbison P. Interventions for relieving the pain and discomfort of screening mammography. Cochrane Database Syst Rev. 2008:CD002942. [PMID: 18254010]
76. Drossaert CH, Boer H, Seydel ER. Health education to improve repeat participation in the Dutch breast cancer screening programme: evaluation of a leaflet tailored to previous participants. Patient Educ Couns. 1996;28:121-31. [PMID: 8852086]
77. Drossaert CH, Boer H, Seydel ER. Monitoring women's experiences during three rounds of breast cancer screening: results from a longitudinal study. J Med Screen. 2002;9:168-75. [PMID: 12518007]
78. Rutter DR, Calnan M, Field S, Vaile MSB. Predicting reattendance in the second round of the UK National Breast Screening Programme: a prospective 3-year longitudinal analysis. Breast. 1997;6:120-5.
79. Aro AR, Absetz-Ylöstalo P, Eerola T, Pamilo M, Lönnqvist J. Pain and discomfort during mammography. Eur J Cancer. 1996;32A:1674-9. [PMID: 8983273]
80. Bennett IC, Robert DA, Osborne JM, Baker CA. Discomfort during mammography: a survey of women attending a breast screening center. Breast Dis. 1994;7:35-41.
81. Drossaert CH, Boer H, Seydel ER. Does mammographic screening and a negative result affect attitudes towards future breast screening? J Med Screen. 2001;8:204-12. [PMID: 11743037]
82. Dullum JR, Lewis EC, Mayer JA. Rates and correlates of discomfort associated with mammography. Radiology. 2000;214:547-52. [PMID: 10671609]
83. Papas MA, Klassen AC. Pain and discomfort associated with mammography among urban low-income African-American women. J Community Health. 2005;30:253-67. [PMID: 15989208]
84. Alimoglu E, Alimoglu MK, Kabaalioglu A, Ceken K, Apaydin A, Lüleci E. [Mammography-related pain and anxiety]. Tani Girisim Radyol. 2004;10:213-7. [PMID: 15470624]
85. Shrestha S, Poulos A. The effect of verbal information on the experience of discomfort in mammography. Radiography. 2001;7:271-7.
86. Sjölin M, Maerker M. [Effects of information on and reflection of women's pain experience during mammography]. Vard Nord Utveckl Forsk. 1994;14:11-5. [PMID: 7941212]
87. Kornguth PJ, Rimer BK, Conaway MR, Sullivan DC, Catoe KE, Stout AL, et al. Impact of patient-controlled compression on the mammography experience. Radiology. 1993;186:99-102. [PMID: 8416595]
88. Poulos A, Rickard M. Compression in mammography and the perception of discomfort. Australas Radiol. 1997;41:247-52. [PMID: 9293675]
89. Lambertz CK. Pre-medication with Acetaminophen for Screening Mammography. Spokane, WA: Gonzaga Univ; 1998.
90. Dibble SL, Israel J, Nussey B, Sayre JW, Brenner RJ, Sickles EA. Mammography with breast cushions. Womens Health Issues. 2005;15:55-63. [PMID: 15767195]
91. Hendrick RE. Radiation doses and cancer risks from breast imaging studies. Radiology. 2010;257:246-53. [PMID: 20736332]
92. Yaffe MJ, Mainprize JG. Risk of radiation-induced breast cancer from mammographic screening. Radiology. 2011;258:98-105. [PMID: 21081671]
93. Friedewald SM, Rafferty EA, Rose SL, Durand MA, Plecha DM, Greenberg JS, et al. Breast cancer screening using tomosynthesis in combination with digital mammography. JAMA. 2014;311:2499-507. [PMID: 25058084]
94. Rose SL, Tidwell AL, Bujnoch LJ, Kushwaha AC, Nordmann AS, Sexton R Jr. Implementation of breast tomosynthesis in a routine screening practice: an observational study. AJR Am J Roentgenol. 2013;200:1401-8. [PMID: 23701081]
95. Ciatto S, Houssami N, Bernardi D, Caumo F, Pellegrini M, Brunelli S, et al. Integration of 3D digital mammography with tomosynthesis for population breast-cancer screening (STORM): a prospective comparison study. Lancet Oncol. 2013;14:583-9. [PMID: 23623721]
96. Skaane P, Bandos AI, Gullien R, Eben EB, Ekseth U, Haakenaasen U, et al. Comparison of digital mammography alone and digital mammography plus tomosynthesis in a population-based screening program. Radiology. 2013;267:47-56. [PMID: 23297332]
97. Haas BM, Kalra V, Geisel J, Raghu M, Durand M, Philpotts LE. Comparison of tomosynthesis plus digital mammography and digital mammography alone for breast cancer screening. Radiology. 2013;269:694-700. [PMID: 23901124]
98. Chiarelli AM, Majpruz V, Brown P, Thériault M, Shumak R, Mai V. The contribution of clinical breast examination to the accuracy of breast screening. J Natl Cancer Inst. 2009;101:1236-43. [PMID: 19720967]
99. de Koning HJ, Draisma G, Fracheboud J, de Bruijn A. Overdiagnosis and overtreatment of breast cancer: microsimulation modelling estimates based on observed screen and clinical data. Breast Cancer Res. 2006;8:202. [PMID: 16524452]
100. Duffy SW, Agbaje O, Tabar L, Vitak B, Bjurstam N, Björneld L, et al. Overdiagnosis and overtreatment of breast cancer: estimates of overdiagnosis from two trials of mammographic screening for breast cancer. Breast Cancer Res. 2005;7:258-65. [PMID: 16457701]
101. Olsen AH, Agbaje OF, Myles JP, Lynge E, Duffy SW. Overdiagnosis, sojourn time, and sensitivity in the Copenhagen mammography screening program. Breast J. 2006;12:338-42. [PMID: 16848843]
102. Paci E, Warwick J, Falini P, Duffy SW. Overdiagnosis in screening: is the increase in breast cancer incidence rates a cause for concern? J Med Screen. 2004;11:23-7. [PMID: 15006110]
103. Paci E, Miccinesi G, Puliti D, Baldazzi P, De Lisi V, Falcini F, et al. Estimate of overdiagnosis of breast cancer due to mammography after adjustment for lead time. A service screening study in Italy. Breast Cancer Res. 2006;8:R68. [PMID: 17147789]
104. Yen MF, Tabár L, Vitak B, Smith RA, Chen HH, Duffy SW. Quantifying the potential problem of overdiagnosis of ductal carcinoma in situ in breast cancer screening. Eur J Cancer. 2003;39:1746-54. [PMID: 12888370]
105. Zahl PH. Overdiagnosis of breast cancer in Denmark [Letter]. Br J Cancer. 2004;90:1686. [PMID: 15083204]
|Author, Year (Reference)||Inclusion Criteria||Searches||Studies, n||Participants, n|
|Bond et al, 201343||Studies in the United Kingdom comparing women with FP vs. normal screening mammograms||Multiple databases through November 2011||7*||3168 (psychological harms); 151,490 (screening reattendance)|
|Hafslund and Nortvedt, 200942||Studies of women aged 40 to 74 y not at high risk invited to mammography screening||Multiple databases; January 1995 to July 2007||17†||18,097|
|Brett et al, 200540||Studies of the psychological effect of mammography screening||Multiple databases; 1982 to 2003||54||NR|
|Brewer et al, 200741||Studies comparing women with FP vs. normal screening mammograms||Multiple databases through September 2006||23||313,967|
|Outcomes in Women With FP vs. Normal Results|
|Screening Reattendance||Anxiety||Depression||Breast Cancer–Specific Worry/Distress|
|Lower with FP result (2 studies)
No difference (2 studies) Higher with FP result if given tailored letters (1 study)
|No difference (2 studies)||No difference (2 studies)||Higher with FP result (3 studies)||Good||Unclear whether the quality of studies was considered in the formulation of conclusions|
|NR||Higher with FP result (15 studies)||NR||Higher with FP result (15 studies)||Fair||Unclear whether the quality of studies was considered in the formulation of conclusions; did not report whether studies were dual-reviewed and dual-abstracted; conflicts of interest were not reported|
|NR||Higher with FP result (14 studies)||NR||Higher with FP result (19 studies)||Fair||Conflicts of interest and quality rating of studies were not reported|
|United States: lower with FP result (RR, 1.07 [95% CI, 1.02 to 1.12]) (5 studies)
Canada: lower with normal result (RR, 0.63 [CI, 0.50 to 0.80]) (2 studies)
Europe: no differences (RR, 0.97 [CI, 0.93 to 1.01]) (5 studies)
|Higher with FP result (4 studies)||Higher with FP result (4 studies)||Fair||Conflicts of interest were not reported; did not formally assess study quality with prespecified criteria|
FP = false-positive; NR = not reported; RR = risk ratio.
* 5 studies were included in ≥1 of the systematic reviews included in the 2009 review.
† 13 studies were included in ≥1 of the systematic reviews included in the 2009 review.
|Author, Year (Reference)||Study Design||Population||Comparisons
(Number of Participants)
|Schou Bredal et al, 201349||Before–after||Women recalled in a screening program in Norway||A: At recall (640)
B: 4 wk later
|HADS (score ≥11)|
|Brodersen and Siersma, 201346||Nested case–control||Screening programs in Denmark||A: FP (272)
B: Normal (864)
C: TP (174)
|Espasa et al, 201248||Case–control||Screening program in Spain||A: FP (100)
B: Normal (50)
|HADS, structured interview|
|Fitzpatrick et al, 201151||Retrospective cohort||Screening program in the United Kingdom||A: FP (9746)
B: Normal (148,589)
|Gibson et al, 200944||Prospective cohort||New Hampshire Mammography Network and the NHWH study||A: FP (2107)
B: Normal (11,384)
|Hafslund et al, 201250||Nested case–control||Screening programs in Norway||A: FP (128)
B: Normal (195)
|Keyzer-Dekker et al, 201245||Prospective cohort||Women with abnormal results in the Netherlands||A: First screen recalls (186)
B: Repeated screen recalls (296)
|STAI, NEO-FFI, CES-D, WHOQOL|
|Klompenhouwer et al, 201452||Retrospective cohort||Screening program in the Netherlands||A: Normal screen (373,474)
B: First screen recalls (6672)
C: Repeated screen recalls for different lesion (161)
D: Repeated screen recalls for same lesion (89)
|Maxwell et al, 201353||Retrospective cohort||Screening program in the United Kingdom||First screening:
A: Open biopsy (110)
B: Needle sampling (1374)
C: No tissue sampling (2703)
A: Open biopsy (199)
B: Needle sampling (1052)
C: No tissue sampling (4009)
|Tosteson et al, 201447||Nested case–control||Women participating in the DMIST in the United States||A: FP (494) immediate
B: FP 1 y after STAI, EuroQol EQ-5D
C: Normal (534) immediate
D: Normal 1 y after
|STAI, EuroQol EQ-5D|
|Screening Reattendance||Anxiety||Depression||Breast Cancer–
|NR||No difference||No difference||NR||NR||NA||Study design not amenable to quality rating|
|NR||Immediate: higher for A + C vs. B; no difference for A vs. C
3 y after: higher for C vs. A + B and A vs. B
|NR||No difference||NR||Good||FP group significantly younger (P < 0.05)|
|Decreased: women aged >55 y, open biopsy, longer time to diagnosis
Increased: repeated screens, screened in mobile unit
|No difference||No difference||Higher for FP vs. normal||NR||Fair||Enrolled selected group of women; did not control for confounders|
|NR||NR||NR||NR||NR||Fair||Did not control for confounders; unclear how women were selected; baseline data not provided for groups of interest|
|NR||NR||Higher for nonwhite with FP vs. normal||NR||NR||Fair||Unclear how women were selected; baseline data not provided for groups of interest; outcomes self-reported|
|NR||No difference||More cases for FP vs. normal||NR||Lower for FP vs. normal||Fair||Enrolled selected group of women; higher response rate in control group|
All recalled groups combined: 44.3%
|No difference*||No difference*||NR||NR||Fair||Outcomes self-reported; older women in repeated screen group; did not report attrition|
|Increased for C but no change for A or B||NR||NR||NR||NR||Fair||Did not control for confounders; baseline data not provided for groups of interest|
|Decreased for A and B but no change for C||NR||NR||NR||NR||Fair||Did not control for confounders; baseline data not provided for groups of interest|
|NR||Decreased from A to B||NR||NR||No difference||Good||FP group significantly younger (P < 0.05)|
|NR||No difference||NR||NR||No difference||-||-|
CES-D = Center for Epidemiologic Studies Depression Scale; COS-BC = Consequences of Screening in Breast Cancer; DMIST = Digital Mammographic Imaging Screening Trial; FP = false-positive; HADS = Hospital Anxiety and Depression Scale; NA = not applicable; NEO-FFI = Neuroticism-Extraversion-Openness Five-Factor Inventory; NHWH = New Hampshire Women for Health; NR = not reported; QOL = quality of life; SF-36 = Short Form-36; STAI = State-Trait Anxiety Inventory; TP = true-positive; WHOQOL = World Health Organization Quality of Life; WHQ = Women's Health Questionnaire.
* Both groups improved over time.
USPSTF = U.S. Preventive Services Task Force.
KQ = key question.
* Excludes women with preexisting breast cancer; clinically significant BRCA1 or BRCA2 mutations, Li-Fraumeni syndrome, Cowden syndrome, hereditary diffuse gastric cancer, or other familial breast cancer syndrome; high-risk lesions (ductal carcinoma in situ, lobular carcinoma in situ, atypical ductal hyperplasia, or atypical lobular hyperplasia); or previous large doses of chest radiation (≥20 Gy) before age 30 y.
† False-positive and false-negative mammography results, biopsy recommendations due to false-positive mammography results, overdiagnosis and
resulting overtreatment, anxiety, pain, and radiation exposure.
‡ Family history; breast density; race/ethnicity; menopausal status; current use of menopausal hormone therapy or oral contraceptives; prior benign
breast biopsy; and, for women aged >50 y, body mass index.
§ Mammography (film, digital, or tomosynthesis), magnetic resonance imaging, ultrasonography, and clinical breast examination (alone or in combination).
RCT = randomized, controlled trial.
* Cochrane Central Register of Controlled Trials and Cochrane Database of Systematic Reviews.
|Author, Year (Reference)||Study Design||Population||Age, y||Participants, n|
|Hubbard et al, 201110||Postintervention series||U.S., 7 mammography registries in the BCSC||40–59||169,456|
|Kerlikowske et al, 201311||Postintervention series||U.S., 7 mammography registries in the BCSC||40–74||11,474 with breast cancer, 922,624 without|
|Elmore et al, 199812||Postintervention series||U.S., randomly sampled patients from 11 health centers in an HMO||40–69||NR|
|Study Years||Comparison||Outcome Measures||Results|
|1994–2006||Annual vs. biennial screening by age||FP results (no diagnosis of invasive carcinoma or DCIS within 1 y of screening or before the next screening mammogram); recalls (BI-RADS 0, 3, 4, 5)||Cumulative probability of FP mammography after 10 y, % (95% CI)
Age 40: annual, 61.3 (59.4 to 63.1); biennial, 41.6 (40.6 to 42.5)
Age 50: annual, 61.3 (58.0 to 64.7); biennial, 42.0 (40.4 to 43.7)
Cumulative probability of FP biopsy after 10 y, % (95% CI)
Age 40: annual, 7.0 (6.1 to 7.8); biennial, 4.8 (4.4 to 5.2)
Age 50: annual, 9.4 (7.4 to 11.5); biennial, 6.4 (5.6 to 7.2)
|1994–2008||Annual vs. biennial vs. triennial screening by age, breast density, and menopausal hormone therapy||FP results (no diagnosis of invasive carcinoma or DCIS within 1 y of screening or before the next screening mammogram); recalls (BI-RADS 0, 3, 4, 5)||Cumulative probability of FP mammography after 10 y, by breast density*, % (95% CI)
Age 40–49: annual: 36 (34 to 38); 60 (59 to 61); 69 (68 to 70); 66 (64 to 67); biennial: 21 (20 to 22); 39 (38 to 39); 46 (46 to 47); 43 (42 to 44); triennial: 14 (13 to 15); 27 (26 to 27); 33 (31 to 34); 33 (32 to 34)
Age 50–74: annual: 30 (29 to 31); 50 (49 to 51); 60 (59 to 61); 59 (57 to 60); biennial: 17 (17 to 18); 31 (30 to 31); 39 (38 to 39); 38 (37 to 38); triennial: 12 (12 to 13); 22 (21 to 22); 28 (28 to 29); 27 (26 to 28)
Cumulative probability of FP biopsy after 10 y, by breast density*, % (95% CI)
Age 40–49: annual: 6 (5 to 7); 9 (8 to 10); 12 (11 to 14); 12 (11 to 14); biennial: 3 (2 to 3); 5 (4 to 5); 7 (6 to 7); 7 (6 to 7); triennial: 2 (2 to 2); 3 (3 to 4); 4 (3 to 4); 3 (2 to 4)
Age 50–74: annual: 5 (5 to 6); 8 (8 to 9); 11 (10 to 12); 11 (10 to 12); biennial: 3 (3 to 3); 5 (4 to 5); 6 (6 to 7); 6 (6 to 7); triennial: 2 (2 to 2); 3 (3 to 4); 5 (4 to 5); 5 (4 to 5)
Highest cumulative rates of FP mammography (66% to 69%) or biopsy (12% to 14%): annual mammography; extremely or heterogeneously dense breasts; age 40–49; used combined hormone therapy
|1983–1995||Annual vs. biennial screening||FP results (not a true positive = breast cancer diagnosed on the basis of pathologic findings within 1 y of mammography)||Cumulative risk for at least one FP after 10 screening mammograms, % (95% CI)
Age 40–49: 56 (39.5 to 75.8)
Age 50–59: 47 (37.8 to 63.0)
Overall: 49 (40.3 to 64.1)
Cumulative risk for FP biopsy, % (95% CI)
Overall: 19 (9.8 to 41.2)
BCSC = Breast Cancer Surveillance Consortium; BI-RADS = Breast Imaging Reporting and Data System; DCIS = ductal carcinoma in situ; FP = false-positive; NR = not reported.
* Almost entirely fat, scattered fibroglandular densities, heterogenously dense, or extremely dense.
|Age, y||Study Years||Data Source||Comparison Groups||Approach,
|Overdiagnosis Measures||Rates of Invasive
Cancer + DCIS
|Rates of Invasive
|Rates of DCIS|
|Bleyer and Welch, 201216||≥40||1976–2008||SEER; United States||Population before vs. after widespread screening||EI; no adjustment||Change in incidence before and after introduction of screening with 3 estimates of baseline incidence
Best guess: incidence increases 0.25% annually
Extreme: incidence increases 0.50% annually
Very extreme: using highest observed incidence, assume a 0.50% incidence increase
|Best guess: 31%
Very extreme: 22%
|Coldman and Phillips, 201317||40–89||1970–2009||Breast cancer registry; Canada||Population before vs. after widespread screening||EI; compensatory drop||Participation estimate: cumulative incidence with active screening vs. never screened or nonactive screening
Population estimate: observed vs. expected population cumulative incidence in 2005–2009
|Participation estimate: 17.3%
Population estimate: 6.7%
|Participation estimate: 5.4%
Population estimate: −0.7%
|de Gelder et al, 201118||49–74||2004–2006||Screening program (biennial); the Netherlands||Modeled incidence of screening vs. predicted incidence without screening||LT; statistical adjustment;
preclinical DCIS: mean 5.2 y; preclinical invasive: 2.6 y
|Microsimulation analysis (digital mammography)
Baseline model: 18% are screen-detectable preclinical DCIS; 11% progress to invasive cancer, 5% are clinically diagnosed, 2% regress
Progressive model: all tumors have preclinical screen-detectable DCIS stage and none regress; 96% invasive with no screening, 4% are clinically diagnosed
Nonprogressive model: no preclinical screen-detected DCIS, majority regress, 2% are clinically diagnosed
|Baseline model: 2.5% all cases; 8.2% screen-detected
Progressive model: 1.4% all cases; 5.0% screen-detected
Nonprogressive model: 7.7% all cases; 25.2% screen-detected
|de Gelder et al, 2011*19||0–69; 0–74||1990–1998; 1998–2007||Screening program (biennial); the Netherlands||Modeled incidence of screening vs. predicted incidence without screening||LT; compensatory drop; mean 2.6 y||Microsimulation screening analysis; excess cancers minus deficit cancers divided by the total number of breast cancers in the absence of screening in women 0-100 y||1-y estimates
1990–1998: 1.0%; 6.1%; 9.1%; 11.4%; 10.0%; 9.4%; 8.8%; 5.6%
1998–2007: 4.9%; 10.0%; 7.4%; 4.7%; 4.7%; 4.9%; 4.3%; 4.4%; 2.8%
|Duffy et al, 201033||50–69||1977–1998; 1974–2003||Swedish Two-County Trial; U.K. National Breast Screening Program||Active vs. passive screening; population before vs. after widespread screening||EI; compensatory drop||Swedish Trial: Estimated expected incidence trends in the prescreening period vs. observed cases, adjusted for prevalence peak
U.K. Program: Observed cases of breast cancer, minus any deficit in ages 65–69 or ≥70 y
|Overall: 4% to 7%
Swedish Trial: 4.3 cases per 1000 women screened for 20 y
U.K. Program: 2.3 cases per 1000 women screened for 20 y
|Falk et al, 2013†20||50–69||1995–2009||Norwegian Breast Cancer Screening Program (biennial)||Women screened vs. those never invited or did not attend screening||EI; compensatory drop||Women attending screening adjusted for adherence to screening vs. 3 reference rates: 40-year-olds 1993–1995
Observed rates of invasive breast cancer 1980–1984
Cohort of women born 1903–1907
|16.5%; 16.3%; 13.9%||11.3%; 11.2%; 9.6%||NR|
|Gunsoy et al, 201432||40–73||1971–2010||Data from various sources in the U.K.||Women screened vs. not screened||Multiple statistical adjustments||Cohort of women born 1903–1907
16.5%; 16.3%; 13.9% 11.3%; 11.2%; 9.6%
Gunsoy et al, 201432
40–73 1971–2010 Data from various sources in the U.K.
Women screened vs. not screened
Multiple statistical adjustments
Markov model of the difference between cumulative incidence of invasive + DCIS with denominators:
Cases diagnosed in absence of screening age 40–85
Cases diagnosed in screening period
Screen-detected breast cancers
|All cases: 4.3 to 8.9%
Screening period: 6.7% to 10.1%
Screen-detected: 11.8% to 13.5%
Highest rates with frequent screening
|Hellquist et al, 201221||40–49||1986–2005||Screening for Young Women Trial; Sweden||Population in areas with vs. without screening||EI; statistical adjustment; up to 1.5 y||Incidence in screening group vs. controls
Corrected for prescreening difference, prevalence peak bias (excluded prevalence screen data), trend bias (change in incidence per year of age)
|Rate ratio: 1.01 (95% CI, 0.94 to 1.08)||Rate ratio: 0.95 (95% CI, 0.88 to 1.01)||NR|
|Jørgensen et al, 2009‡22||50–69||1991–2003 vs. 1971–1990||Screening program; Copenhagen and Funen, Denmark||Population in areas with (1991–2003) vs. without (1971–1990) screening||EI; compensatory drop||Ratio of incidence between screened and nonscreened areas for the screened age group||33%||NR||NR|
|Kalager et al, 2012§23||50–69||1996–2005||Norwegian Breast Cancer Screening Program (biennial)||Population in areas with vs. without screening||EI; compensatory drop; approach
1: 10-y lead time; approach
2: 5 or 2 y
|Approach 1: Incidence rates in the screening and nonscreening groups for women aged 50–79 y
Approach 2: Excluded all cases of cancer detected in the first screening round, compares incidence in screened women vs. women 2–5 y older
|NR||Approach 1: entire country: 25%, region 1: 18%
Approach 2: 5-y lead time: 15%,
2-y lead time: 20%
|Martinez-Alonso et al, 201024||40–69||1980–2004||Cancer registry; Catalonia, Spain||Modeled pre vs. post screening incidence||EI; statistical adjustments||Probabilistic model for birth cohorts: 1935, 1940, 1945, 1950; observed vs. expected cumulative incidence||NR||1935: 0.4%
|Miller et al, 201431||40–59||1980–1985||Canadian National Breast Screening Study||Randomized trial; screening vs. usual care||EI; none||Excess of breast cancer cases in mammography group vs.control group of trial||NR||22% of screen-detected cancer||NR|
|Morrell et al, 201025||50–69||1999–2001||Screening program (biennial); Australia||Screened vs. unscreened age group or before screening implementation||EI; statistical adjustment;
2- or 5-y lead times
|Observed annual incidence minus expected annual incidence divided by expected annual incidence
Interpolation approach: incidence in unscreened women (≤40 or ≥80) modeled by 5-y age group
Extrapolation approach: incidence for the period before the introduction of screening modeled for all 5-y age groups and extrapolated to 1999–2001
|NR||Interpolation: 2-y: 51%; 5-y: 42%;
Extrapolation: 2-y: 36%, 5-y: 30%
Rates higher for 50–59 vs. 60–69
|Njor et al, 201326||56–70||1991–2005||Screening program; Copenhagen and Funen, Denmark||Population in areas with vs. without screening||EI; compensatory drop||Cumulative incidence in screened population vs. expected incidence in unscreened counties||≥8 y follow-up: Copenhagen, 3%(−14% to 25%), Funen, 0.7% (−9% to 12%)||NR||NR|
|Puliti et al, 200927||60–69||1990–NR||Screening program; Florence, Italy||Screening vs. prescreening||EI; compensatory drop||Ratio of cumulative incidence of breast cancer in the invited group to those in the noninvited group at least 5 y after last screening, assuming 1.2% annual trend in prescreening incidence||Rate ratio: 1.01 (95% CI, 0.95 to 1.07)||Rate ratio: 0.99 (95% CI, 0.94 to 1.05)||NR|
|Seigneurin et al, 201128||50–69||Cancer registry; Isere, France||Modeled screening incidence||LT; statistical adjustment, 2–4 y||LT; statistical adjustment, 2–4 y||Stochastic simulation model, driven by all-cause mortality, lifetime probability of breast cancer, natural course of breast cancer, and cancer detection; adjusted for sojourn time||NR||All diagnosed cancers: 1.5%, screen-detected: 3.3%||All diagnosed cancers: 28.0%, screen-detected: 31.9%|
|Yen et al, 201229||40–74||Swedish Two-County Trial; data from one county only (Dalarna)||Active screening vs. passive screening||EI; compensatory drop||EI; compensatory drop||Cumulative incidence in active screening vs. usual care groups||Relative risk: 1.00 (95% CI, 0.92 to 1.08)||Relative risk: 0.99 (95% CI, 0.88 to 1.55)||Relative risk: 1.17 (95% CI, 0.88 to 1.55)|
|Zahl and Mæhlen, 201230||40–79||1991–2009||Norway Cancer Registry||Screening vs. postscreening||EI; compensatory drop||Define overdiagnosis as increase in number of cancer diagnoses among those who are invited for screening and the reduction in the number of diagnoses among those no longer invited||50%||NR||NR|
|de Koning et al, 200699||50–74||1989–2001||National data from the Netherlands||Screening vs. nonscreening (biennial)||Statistical adjustments; assumptions of DCIS progression||Microsimulation model||3% in screened population; 8% screen-detected||NR||NR|
|Duffy et al, 2005100||40–74
|Swedish Two-County Trial
|Active vs. passive screening
Screening vs. no screening
|Lead-time statistical adjustments
Lead-time statistical adjustments
|Markov multistate model
Markov multistate model
|1% in screened population
2% in screened population
|Olsen et al, 2006101||50–71||1991–1996||Copenhagen, Denmark; screening program (biennial)||Incidence in screened women||Statistical adjustments||Chronic disease statistical model of screen-detected overdiagnosis||Prevalence: 7.8%
|Paci et al, 2004102||50–69||1985–1999||Florence, Italy; screening program||Incidence in screening vs. prescreening||EI; corrected for lead time||Observed/expected cases||5%||2%||3%|
|Paci et al, 2006103||50–74||1986–2001||Italy; screening program||Prescreening incidence||EI; corrected for lead time||Observed/expected cases||4.6%; range −0.6% to 9.7% varies by age (highest in 50–54 and 65–74)||3.2%||1.4%|
|Yen et al, 2003104||40–69
|Swedish Two-County Trial, United Kingdom, the Netherlands, Australia, New York
Swedish Two-County Trial
|Screening vs. no screening
Screening vs. no screening
|LT; statistical adjustment
LT; statistical adjustment
|6-state Markov model
6-state Markov model
40–49: 19%, 3%
50–59: 23%, 4%
60–69: 46%, 6%
|Zackrisson et al, 200634||55–69||1978–1986||Malmö trial||Randomized screening vs. no screening||EI; compensatory drop||Comparison of incidence in screened vs. unscreened||10% of incidence in control group||7%||3%|
|Zahl, 2004105||50–69||1971–2000||Norway and Sweden||Prescreening incidence||EI; compensatory drop||Changes in age-specific incidence rates associated with the introduction of screening programs||NR||30% of incidence in screened population||NR|
DCIS = ductal carcinoma in situ; EI = excess incidence approach; LT = lead-time approach; NR = not reported; SEER = Surveillance, Epidemiology, and End Results Program.
* Additional 6 model estimates for each year are published in this paper to show that the range of estimates varies by selection of the denominator.
† Population overlap with Kalager and colleagues.23
‡ Same Copenhagen population as Olsen and colleagues.101
§ Population overlap with Falk and colleagues.20
|Inclusion Criteria||Searches||Studies, n (Designs);
|Whelehan et al, 201374||Studies of pain or discomfort of screening mammography and reattendance||MEDLINE, EMBASE, PsycINFO, CINAHL, ASSIA, Cochrane Database of Systematic Reviews, Sociological Abstracts, SSCI, SCI, and NHS online literature database; October 2012||20 (most cross-sectional surveys); causation (n = 5741); association (n = NR)||Quality based on individual factors*; studies combined separately for causation vs. association||Causation (7 studies); response rates: 32%-79%
Actual nonreattendance indicating pain as the reason (5 studies): 11%-46%
Intended future nonreattendance due to pain (2 studies): 2.7% and 17.5%
Association (15 studies)
Actual reattendance (10 studies): no difference between women who experienced pain vs. no pain (RR, 1.38 [95% CI, 0.94 to 2.02]; 5 studies); higher pain scores in nonreattenders vs. reattenders in 2 of 3 studies (P = 0.001 and P < 0.05)
Intended reattendance (5 studies): no differences (3 studies), less intent for women with pain (2 studies) with OR of 0.61 (95% CI, 0.38 to 0.98) in 1 study
|Fair||Unclear how study quality was used to formulate conclusions; did not describe characteristics of all included studies; did not assess publication bias|
|Armstrong et al, 200773||Studies of risks of screening mammography for women in their 40s||MEDLINE, PreMEDLINE, and the Cochrane Central Register of Controlled Trials; May 2005||22 (3 RCTs, 5 prospective cohort, 1 retrospective cohort, 13 cross-sectional); 13,008||Centre for Evidence-based Medicine criteria; based on study design and rates of attrition; methods of synthesis not described||Prevalence of pain from mammography varied from 28%-77%
Degree of pain was associated with stage of menstrual cycle (3 studies), anxiety (2 studies), and premammography anticipation of pain (4 studies)
|Fair||No synthesis of data; unclear how study quality was used to formulate conclusions; study designs not prespecified; did not assess publication bias|
|Miller et al, 200875||RCTs of interventions that reduce or relieve the pain and discomfort of
|MEDLINE, EMBASE, CINAHL, and Cochrane Breast Cancer Specialised Register; 2006||7 (RCTs); 1771||Based on generation and concealment of allocation sequence, comparability of groups at baseline,intention-to-treat analysis, and double-blinding after allocation||Information provided before mammography vs. usual care (3 trials): 44% vs. 24% (P = 0.009) experienced less discomfort than expected with verbal information (1 trial)
Pain scores were lower with written information in 1 trial (mean VAS score, 16.5 vs. 24.5; P < 0.05), but no differences were found in another trial
Breast compression strategies (2 trials):
Participant vs. technologist compression indicated 57% felt no difference in discomfort, 31% less, 13% more
No difference with normal vs. 1 second of reduced compression
Premedication (1 study): acetaminophen vs. none (mean VAS scores, 23.7 vs. 22.8; P = 0.896)
Breast cushion (1 study): reduced pain for cushion vs. no cushion (mean VAS pain score, 20.34 vs. 34.94; P < 0.0001)
|Good||Did not assess publication bias|
ASSIA = Applied Social Sciences Index and Abstracts; NHS = National Health Service; NR = not reported; OR = odds ratio; RCT = randomized, controlled trial; RR = risk ratio; SCI = Science Citation Index; SSCI = Social Sciences Citation Index; VAS = visual analogue scale.
* Includes whether intended or actual reattendance was measured, survey response rate/participation rate, measures of pain or discomfort, consistency of the timing of outcome measurement, quality of statistical analysis, and robustness of ascertaining reattendance rate.
|Study Design||Population||Age, y||Method||Outcome Measures||Results|
|Hendrick, 201091||Modeling study||U.S.-based sources||40 to 80||Theoretical estimates based on long-term follow-up of acute exposures to higher levels of ionizing radiation and a linear no-threshold extrapolation of risks at low doses. Model assumes 3.7 to 4.7 mGy per examination.||Breast cancer cases and mortality||LAR of breast cancer incidence and mortality, per 100,000 women:
40 y: 5-7 cases; 1.3-1.7 deaths
50 y: 2-3 cases; 0.7-0.9 deaths
80 y: 0.1-0.2 cases; <0.1 death
LAR of breast cancer incidence and mortality in women undergoing annual screening mammography, per 100,000 women:
Screening 40-80 y: 72-91 cases; 20-25 deaths
Screening 50-80 y: 31-40 cases; 10-12 deaths
|Yaffe and Mainprize, 201192||Modeling study||U.S.-based sources||40 to 74||Model based on digital mammography and radiation exposure estimates of 3.7 mGy per examination.||Estimated lifetime radiation-induced breast cancer cases and deaths||Number of radiation-induced breast cancer cases and deaths in 100,000 women:
Annual 40-49 y: 59 cases; 7.6 deaths
Annual 50-59 y: 27 cases; 3.1 deaths
Biennial 50-59 y: 14 cases; 1.6 deaths
Annual 40-59 y: 85 cases; 11 deaths
Annual 40-49 y, biennial to 59 y: 73 cases; 9 deaths
Annual 40-55 y, biennial to 74 y: 86 cases; 11 deaths
LAR = lifetime attributable risk.
|Study Design||Population||Age, y||Study
|Mammography with or without tomosynthesis|
|Haas et al, 201397||Case series||United States; multisite hospital and outpatient centers||All ages||2011 to 2012||DM (7058) vs. DM plus tomosynthesis (6100)||Recall rate (%); adjusted odds of recall||Recall, DM vs. DM plus tomosynthesis, by age (relative change [95% CI]):
All ages: 8.4% vs. 12.0%; −29.7% (−19.1% to −36.5%); P < 0.01
40 to 49 y: 10.4% vs. 16.3%; −35.8% (−24.2% to −45.7%); P < 0.01
50 to 59 y: 7.6% vs. 10.6%; −28.0% (−12.7% to −44.6%); P < 0.01
60 to 69 y: 7.4% vs. 10.7%; −30.3% (−12.3% to −44.6%); P = 0.01
≥70 y: 6.7% vs. 7.9%; −15.4% (NS)
Adjusted recall OR (95% CI): 0.62 (0.55 to 0.70); P < 0.0001
|Friedewald et al, 201493||Postintervention series||United States; multicenter||Mean: 57||2010 to 2012||DM (281,187) vs. DM plus tomosynthesis (173,663)||Recall and biopsy rates per 1000 women||Recall, DM vs. DM plus tomosynthesis (change [95% CI]): 107/1000 vs. 91/1000; −16.1 (−18.0 to −14.2); P < 0.001
Biopsy, DM vs. DM plus tomosynthesis (change [95% CI]): 18.1/1000 vs. 19.3/1000; 1.3 (0.4 to 2.1); P = 0.004
|Rose et al, 201394||Case series||United States; multisite community-based breast center||>18||2011 to 2012||DM (18,202) vs. DM plus tomosynthesis (10,878)||Recall rate (%)||Recall, DM vs. DM plus tomosynthesis by age (relative change):
All ages: 8.7% vs. 5.5%; −37.5%; NS
<50 y: 10.3% vs. 6.5%; −37.2%
50–64 y: 7.6% vs. 5.1%; −32.9%
>64 y: 7.9% vs. 4.2%; −46.6%
|Ciatto et al, 201395||Postintervention series||Italy; population-based screening program (STORM)||≥48||2011 to June 2012||Biennial DM vs. DM plus tomosynthesis (total: 7292)||Recall rate (%)||Recall, DM vs. DM plus tomosynthesis:
All ages: 141 (2%) vs. 73 (1%); P < 0.0001
<60 y: 89 (2.2%) vs. 41 (1.0%)
>60 y: 52 (2%) vs. 32 (1%)
|Skaane et al, 201396||Postintervention series||Oslo, Norway, screening program||50 to 69||2010 to 2011||Biennial DM vs. DM plus tomosynthesis (total: 12,631)||Recall rate per 1000 women||Recall, DM vs. DM plus tomosynthesis: 61.1/1000 vs. 53.1/1000 (−13%); RR, 0.85; P < 0.001|
|Mammography with or without CBE|
|Chiarelli et al, 200998||Cohort||Canada||40 to 69||2002 to 2003||Biennial mammography (57,715) vs. CBE plus
|Recall rate (%)||Recall, mammography vs. CBE with or without mammography: 6.5% vs. 8.7% (2.2% increase for CBE) or 55/10,000 additional FP results with CBE|
CBE = clinical breast examination; DM = digital mammography; FP = false-positive; NS = not statistically significant; OR = odds ratio; RR = risk ratio; STORM = Screening with Tomosynthesis or Standard Mammography.